TherapeuticsMD (NASDAQ:TXMD) received a $14.00 price objective from stock analysts at Oppenheimer in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the stock. Oppenheimer’s price target points to a potential upside of 181.69% from the stock’s current price.
TXMD has been the subject of a number of other research reports. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. Zacks Investment Research upgraded TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Wednesday, October 17th. Cantor Fitzgerald set a $27.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Sunday, October 14th. JPMorgan Chase & Co. set a $11.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, August 15th. Finally, BidaskClub downgraded TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $13.45.
Shares of TherapeuticsMD stock opened at $4.97 on Wednesday. The company has a quick ratio of 7.79, a current ratio of 7.88 and a debt-to-equity ratio of 0.94. The company has a market cap of $1.09 billion, a P/E ratio of -13.43 and a beta of 1.40. TherapeuticsMD has a 52 week low of $4.30 and a 52 week high of $7.66.
In related news, CEO Robert G. Finizio sold 184,000 shares of the company’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $6.24, for a total value of $1,148,160.00. Following the sale, the chief executive officer now directly owns 18,485,559 shares of the company’s stock, valued at $115,349,888.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Brian Bernick sold 182,800 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $6.30, for a total value of $1,151,640.00. Following the completion of the sale, the director now directly owns 242,000 shares in the company, valued at $1,524,600. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,158,800 shares of company stock worth $12,946,562. 22.85% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. Iridian Asset Management LLC CT grew its stake in TherapeuticsMD by 20.3% in the second quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock worth $430,000 after purchasing an additional 11,629 shares during the period. Xact Kapitalforvaltning AB grew its stake in TherapeuticsMD by 96.3% in the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after purchasing an additional 15,600 shares during the period. Swiss National Bank grew its stake in TherapeuticsMD by 6.3% in the second quarter. Swiss National Bank now owns 320,300 shares of the company’s stock worth $1,997,000 after purchasing an additional 18,900 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of TherapeuticsMD in the second quarter worth $121,000. Finally, Managed Account Services Inc. purchased a new stake in shares of TherapeuticsMD in the third quarter worth $117,000. 66.20% of the stock is currently owned by institutional investors.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.